Barchart.com
[[ type === 'moc' ? 'MARKET ON CLOSE' : 'FREE WEBINAR' ]]
[[ timeLabel ]] WATCH LIVE:
Your browser of choice has not been tested for use with Barchart.com. If you have issues, please download one of the browsers listed here.
Jump-Start Your Search For Promising Trade Ideas With Barchart Premier’s "Top Stock Pick". FREE 30 Day Trial
Menu
Stocks | Futures | Watchlist | News | More
 
or
Watchlist | Portfolio | Dashboard
Site News
Contact
Market:
Faster, Cleaner, Better.
Menu

Zevra Therapeutics Inc (ZVRA)

Zevra Therapeutics Inc (ZVRA)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] by (Cboe BZX)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] [[ item.lastPriceExt ]] [[ item.priceChangeExt ]] ([[ item.percentChangeExt ]]) [[ item.tradeTimeExt ]]
News & Headlines for [[ item.sessionDateDisplayLong ]]
Notes
Alerts
Watch
Help
Go To:
Zevra Therapeutics Announces Publication of Positive MIPLYFFA® Data from Pediatric Substudy in Infants with Niemann-Pick Disease Type C (NPC) GlobeNewswire - Tue Jun 23, 6:30AM CDT

BOSTON, June 23, 2026 (GLOBE NEWSWIRE) -- Zevra Therapeutics, Inc. (NasdaqGS: ZVRA) (Zevra, or the Company), a commercial-stage company focused on bringing life-changing therapeutics to people living...

ZVRA : 13.98 (+1.23%)
Zevra’s Chief Medical Officer to Step Down for Personal Reasons as Part of Planned Transition GlobeNewswire - Thu Jun 11, 7:30AM CDT

BOSTON, June 11, 2026 (GLOBE NEWSWIRE) -- Zevra Therapeutics, Inc. (NasdaqGS: ZVRA) (Zevra, or the Company), a commercial-stage company focused on bringing life-changing therapeutics to people living...

ZVRA : 13.98 (+1.23%)
Zevra Therapeutics Announces Orange Book Listing of U.S. Patent Strengthening Exclusivity for MIPLYFFA GlobeNewswire - Mon Jun 8, 6:30AM CDT

MIPLYFFA  patent submitted for Orange Book listing, with patent protection to 2041 Separately filed patent term extension remains pending with the U.S. Patent and Trademark Office BOSTON, June...

ZVRA : 13.98 (+1.23%)
Zevra Therapeutics Announces Inducement Grants under Nasdaq Listing Rule 5635(c)(4) GlobeNewswire - Fri May 29, 3:30PM CDT

BOSTON, May 29, 2026 (GLOBE NEWSWIRE) -- Zevra Therapeutics, Inc. (NasdaqGS: ZVRA) (Zevra, or the Company), a commercial-stage company focused on bringing life-changing therapeutics to people living...

ZVRA : 13.98 (+1.23%)
Zevra Therapeutics to Present at the H.C. Wainwright BioConnect Investor Conference GlobeNewswire - Tue May 12, 6:30AM CDT

BOSTON, May 12, 2026 (GLOBE NEWSWIRE) -- Zevra Therapeutics, Inc. (NasdaqGS: ZVRA) (Zevra, or the Company), a commercial-stage company focused on providing therapies for people living with rare disease,...

ZVRA : 13.98 (+1.23%)
Zevra Therapeutics: Q1 Earnings Snapshot AP - Wed May 6, 3:52PM CDT

Zevra Therapeutics: Q1 Earnings Snapshot

ZVRA : 13.98 (+1.23%)
Zevra Reports First Quarter 2026 Financial Results and Corporate Update GlobeNewswire - Wed May 6, 3:05PM CDT

Q1 2026 net revenue of $36.2 million , a 78% increase over Q1 2025 Completed $50.0 million sale of SDX portfolio to Commave Therapeutics Operational execution fueled strong cash position...

ZVRA : 13.98 (+1.23%)
Zevra's Rare Disease Portfolio May Finally Have Enough Market Traction to Revalue Barchart - Tue May 5, 4:42PM CDT

Barchart Research What to Expect from ZVRA Earnings ZVRA Generated May 5, 2026 Current Price $10.61 EPS Estimate $$0.06 Consensus Rating Strong Buy Average Move 7.85% Zevra's Rare Disease Portfolio May...

ZVRA : 13.98 (+1.23%)
Zevra Therapeutics Announces Details for Q1 2026 Financial Results Call GlobeNewswire - Wed Apr 22, 6:30AM CDT

BOSTON, April 22, 2026 (GLOBE NEWSWIRE) -- Zevra Therapeutics, Inc. (NasdaqGS: ZVRA) (Zevra, or the Company), a commercial-stage company focused on providing therapies for people living with rare disease,...

ZVRA : 13.98 (+1.23%)
Zevra Therapeutics Reports Inducement Grant to New Chief Financial Officer Under Nasdaq Listing Rule 5635(c)(4) GlobeNewswire - Fri Mar 20, 3:30PM CDT

BOSTON, March 20, 2026 (GLOBE NEWSWIRE) -- Zevra Therapeutics, Inc. (NasdaqGS: ZVRA) (Zevra, or the Company), a commercial-stage company focused on providing therapies for people living with rare disease,...

ZVRA : 13.98 (+1.23%)

Barchart Exclusives

Cathie Wood Sees Value in This Beaten-Down Growth Stock. I Do Too. Barchart - 1 hour ago
Cathie Wood has bought SoFi shares alongside several other fintech names. The stock has underperformed this year but seems poised for a comeback in the back half of the year. Read more
Want to use this as
your default charts setting?
Save this setup as a Chart Templates
Switch the Market flag
for targeted data from your country of choice.
Open the menu and switch the
Market flag for targeted data from your country of choice.
Want Streaming Chart Updates?
Switch your Site Preferences
to use Interactive Charts
Need More Chart Options?
Right-click on the chart to open the Interactive Chart menu.
Use your up/down arrows to move through the symbols.